Weekly injections of somatrogon result in similar height gains to daily somatropin treatment in children with growth hormone deficiency, show results of a 12-month phase 3 trial.
An oral growth hormone secretagogue receptor agonist produces larger GH responses than standard stimulation tests in children with growth hormone deficiency, study findings suggest.
A study of Brazilian children with isolated SHOX haploinsufficency who were followed up until adult height has demonstrated a long-term benefit of recombinant human growth hormone therapy with or without puberty modulator treatment.
A 4-year-old girl is referred to the local paediatric endocrine unit with signs of pubertal development.
Children with growth hormone deficiency maintain their growth trajectories if they switch from a daily recombinant human growth hormone to weekly lonapegsomatropin, and the vast majority prefer the less frequent injections, show the results of the fliGHt trial.
Treatment with recombinant human growth hormone results in an increased final adult height in children with molecularly confirmed Silver–Russell syndrome, as well as an improved BMI that persists after treatment cessation, say researchers.
The benefit of initiating recombinant human growth hormone before puberty in patients with Noonan syndrome occurs regardless of whether the children carry a PTPN11 mutation, suggests research published in Endocrine Connections.
Blood-cell markers of inflammation are elevated in children with Cushing’s syndrome and may offer useful diagnostic information, say researchers.
The 3-year findings of the REAL 3 trial show that weekly somapacitan continued to deliver equivalent height gains and safety results to that achieved with standard daily recombinant human growth hormone treatment in children with growth hormone deficiency.
Treatment with recombinant human growth hormone is not associated with cardiovascular adverse events in clinical practice, show data from two large, multicentre cohorts.
